Uttar Pradesh Journal of Zoology

Volume 45, Issue 15, Page 387-393, 2024; Article no.UPJOZ.3788
ISSN: 0256-971X (P)

Exploring the Anti-diabetic Properties of Edible Mushrooms: A Comprehensive Review

H.Rama Subba Reddy [a*], M.Vijaya Kumar [b], G.Lakshmaiah [c], K.Harish Babu [d], C.Aruna [e], D. Veera Nagendra Kumar [f] and V.Uday Kiran [g*]

[a] Department of Zoology, SVB. Govt. Degree College, Koilkuntla, Nandyala (D.T), AP, India.
[b] Department of Zoology, Govt. Degree College, Eluru, Eluru (D.T), AP, India.
[c] Department of Zoology, GVRS. Govt. Degree College, Dhone, Nandyal (D.T), AP, India.
[d] Department of Zoology, PS. Govt. Degree College, Penukonda, Sri Satya Sai (D.T), AP, India.
[e] Department of Botany, Dr.YSRGovt Degree College, Vedurukuppam, Chittoor(D.T)-AP, India.
[f] Department of Zoology, Government College for Men (A), Kadapa-Ap, India.
[g] Department of Zoology, Loyola Degree College (YSRR) Pulivendula-AP, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: https://doi.org/10.56557/upjoz/2024/v45i154255

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers,peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://prh.mbimph.com/review-history/3788

Review Article

Received: 10/05/2024
Accepted: 12/07/2024
Published: 15/07/2024

ABSTRACT

Mushrooms, part of the "Fungi" family is well-known for their medical benefits and accessibility globally. Diabetes has become more commonplace worldwide in recent times, which has made the search for alternate treatment approaches necessary. Because of their possible anti-diabetic

**Corresponding author: Email: hanumanthu.subbareddy@gmail.com, vempati.uday6@gmail.com;*

Cite as: *Reddy, H.Rama Subba, M.Vijaya Kumar, G. Lakshmaiah, K.Harish Babu, C. Aruna, D. Veera Nagendra Kumar, and V.Uday Kiran. 2024. "Exploring the Anti-Diabetic Properties of Edible Mushrooms: A Comprehensive Review". UTTAR PRADESH JOURNAL OF ZOOLOGY 45 (15):387-93. https://doi.org/10.56557/upjoz/2024/v45i154255.*

effects, edible mushrooms—a natural source of bioactive compounds—have drawn interest. This research assesses the possible anti-diabetic benefits of edible mushrooms, concentrating on their bioactive constituents and mechanisms that modulate insulin sensitivity and glucose metabolism, and emphasises their potential significance in diabetes prevention. The review concludes that EM can predict insulin resistance through active chemicals like polysaccharides and vitamin D, as well as preventative activities like β-glucosidase and β-amylase. The therapeutic benefits of many mushroom types have not been thoroughly researched, and the mechanism remains unclear. More study on edible medicinal mushrooms is needed to fully utilise their therapeutic promise in preventing noncommunicable diseases.

Keywords: Anti-diabetic abilities; biochemical; molecular aspects; bioactive compounds.

1. INTRODUCTION

Mushrooms, whose come from the Latin and Greek terms "fungus" and "mykes," are deemed edible if they do not create health problems. They are classified into edible, inedible, and non-poisonous varieties [1]. For thousands of years, mushrooms have been utilised as food and medicine in Asian and South Asian countries such as China, Japan, India, and Taiwan [2]. Mushrooms are highly nutritious, with 34 billion kg produced and 4.7 kg per capita consumption in 2013 [3]. They are high in protein, vitamins, B vitamins, vitamin D, vitamin K, and, in rare cases, vitamins A and C [4]. They are also low in fat, high in dietary fibre, nutraceuticals and polysaccharides, all of which have beneficial health effects [5]. Diabetes mellitus (DM) is a category of non-communicable metabolic illnesses characterised by chronic hyperglycemia caused by insulin secretion or action deficiencies [6]. Diabetes is characterised as type 1 (T1DM), type 2 (T2DM), or gestational diabetes mellitus. Diabetes currently affects 415 million people and is estimated to reach 642 million by 2040 [7].T1DM is associated with an autoimmune condition, whereas T2DM results in glucotoxicity and endoplasmic reticulum-induced stress [8]. Polydipsia, polyphagia, polyuria, and nocturia are common symptoms, and micro vascular and macro vascular abnormalities might occur as consequences. Insulin resistance is a key cause of diabetic complications [9].

Fig. 1. List of various edible mushrooms and their properties
Source: https://www.researchgate.net

This review investigates the function of edible mushrooms in diabetes mellitus treatment by looking at bioactive components, insulin resistance patho-physiology, and prevention strategies [10-14]. Data from 50 scholarly publications were collected to identify 10 common edible mushroom types [10,15]. The review also looked at various species and hypoglycemic drugs, analysing both *in vivo* and *in vitro* data. The data is shown in Fig. 1.

2. DIABETES MELLITUS AND INSULIN RESISTANCE

Diabetes Mellitus (T2DM) is a developing global problem, and obesity plays an important part in its development [16]. Insulin resistance (IR) is also rising in T1DM. T2DM affects insulin production by 50% and insulin sensitivity in peripheral tissues by up to 70%. Insulin operates by phosphorylating PI3K and Akt, which activates glucose transporter 4 [17]. Insulin sensitivity is a condition in which normal plasma insulin levels fail to control blood glucose levels [18]. IR is linked to a variety of disorders, including cardiovascular disease, nonalcoholic fatty liver disease and cancer [19]. Diabetes is a chronic metabolic condition characterised by high blood glucose levels as a result of impaired insulin secretion and action [20]. Insulin resistance, a defining feature of type 2 diabetes, is caused by a combination of genetic and environmental factors [21]. It is characterised by dysregulation of adipokines, cytokines, and lipid metabolism, which results in inflammation and lipid buildup [21]. Diagnosing insulin resistance is critical for early intervention and prevention [22]. Lifestyle changes and pharmaceutical therapies can help increase insulin sensitivity and glycemic management [23].

3. EATING EDIBLE MUSHROOMS CAN HELP PREVENT DIABETES AND INSULIN RESISTANCE

Diabetes mellitus and insulin resistance offer substantial health risks, necessitating the development of preventative methods, such as dietary interventions [24]. Edible mushrooms, which contain bioactive chemicals, have the ability to prevent certain diseases via a variety of ways [25]. These include antioxidant, anti-inflammatory, and insulin-sensitizing qualities that reduce oxidative stress and inflammation, increase insulin sensitivity and glucose metabolism, and control critical signalling pathways involved in glucose and lipid metabolism [25,26].Mushrooms also improve insulin secretion and pancreatic function. However, further study is needed to ensure that mushroom-derived medicines are as effective and safe as possible [27].

3.1 Polysaccharide Lowers Blood Glucose Levels

Polysaccharides are biopolymers composed of simple sugars or monosaccharides connected by glycosidic bonds [28]. Mushroom extracts high in ß-D-glucans have showed potential health advantages against type 2 diabetes [29]. These extracts control glycogen synthesis and blood glucose levels via modulating gene expression in the liver and muscle, avoiding insulin resistance by inhibiting acylase and glucosidase activity, and enabling the PI3K/AKT pathways [30].

3.2 Reduction in the Absorption of Glucose

Mushrooms slow down digestion rates and delay the absorption of glucose due to their water-soluble dietary fibre content, which causes a postprandial glucose spike [31]. Numerous studies have demonstrated the significant blood glucose-lowering effects of mushrooms, particularly *Pleurotus spp.Grifolafrondosa*, *Agaricus bisporus*, *Hericium erinaceus* and *Ganoderma lucidum* [32]. This is because they delay the absorption of glucose, which improves hyperglycaemic conditions [33].

3.3 Sustains the Activity of Pancreatic ß Cells

The polysaccharides found in mushrooms, called ß-D-glucan, have strong immune modulating properties [34]. They also inhibit oxidative damage and inhibit the activation of pro-inflammatory cytokines by decreasing NF-kB activity [35]. Glucotoxicity is inhibited and pancreatic ß-cell death is prevented by bioactive components from mushrooms, particularly polysaccharides [36]. Additionally, research has demonstrated that ß-cell proliferation is maintained and ß-cell functionality is significantly impacted by mushroom extracts from *Pleurotus spp*., Boletus, *Agaricus bisporus*, and *Hericium erinaceus* [37].

3.4 Terpenoids' Hypoglycemic Effect on Blood

Blood glucose levels are raised by enzymes like -glucosidase and \-amylase, which hydrolyze

oligosaccharides to monosaccharides [35,25]. Terpenoids (monoterpenes, diterpenes, sesquiterpenes, and triterpenes) from *Plagiophorus spp.Laetiporussulphurous, Tremella fuciformis*, *Ganoderma lucidum* and *Pholiota microspore* are thought to possess a β-glucosidase inhibitory activity that hinders the formation of monosaccharide molecules and promotes the formation of glycogen in the liver and muscle [36].

3.5 Vitamin D's Function in Blood Glucose Regulations

Unlike plants, mushrooms belong to the fungus kingdom and have a high ergosterol content in their cell walls [38]. Ergosterol in the mushroom cell wall is converted to pre-vitamin D2 and then thermally isomerized to ergocalciferol, or vitamin D2, when exposed to sunlight [26,27]. The hydroxy vitamin D, also known as 1, 25-dihydroxy vitamin D, is crucial for maintaining glucose homeostasis [39]. By acting directly on ß-cells and indirectly on other immune cells such as dendritic cells, inflammatory macrophages, and other T cells, it also shields ß-cells from damaging immunological assaults [22,28]. By controlling the intracellular calcium concentration, vitamin D sustains insulin production through molecular processes [16,20]. Vitamin D promotes PLC production, PKA activation, and Ca+ absorption with the aid of calbindin. Consequently, the vitamin mediates the genomic mode of action of vitamin D. D receptor (VDR) [17,19]. Vitamin D's active form, 1,25 (OH)2 D3, attaches itself to VDR and joins forces with the retinoid receptors (RXR) to form a heterodimer [9,7]. The 1,25 (OH)2 D3-VDR-RXR complex is moved into the nucleus and bound to vitamin D-responsive elements (VDRE), allowing for the prevention of insulin resistance and the facilitation of epigenetic modifications [36].



Fig. 2. Benefits of terpenoids (mono-, di-, sesquiterpene, and triterpene) found in mushrooms



Fig. 3. Proposal-mechanisms-underlying-the-beneficial-effects-of-vitamin-D-for-glucose
Source: https://www.researchgate.net

Briefly put, vitamin D functions in a variety of ways, including immune regulation, proliferation prevention, inherited gene polymorphism, anti-inflammatory (reducing the effects of pro-inflammatory cytokines, TNF-, IL-8b, and IL-6), and, finally, regulating adipokine production to prevent insulin resistance (through IRS, AKT, PPARy, and VDRE gene regulations) [2,9].

According to the facts at hand, there is still disagreement among scientists on the bioavailability of vitamin D in the treatment of diabetes [39]. But button mushrooms treated with UV-B can increase vitamin D2 bioavailability among human participants, and the significant value does not change when vitamin D2 supplements are taken, according to recent findings using data from randomised placebo trials [22]. According to many researches has shown the beneficial effects of vitamin D supplementation (2000IU and 30,000IU) on type 2 diabetes (T2DM), albeit more studies are needed [40]. Because of this, it is still unclear how precisely vitamin D works and how much of it is needed to cure diabetes mellitus [40].

4. CONCLUSIONS

The review looks at the potential medical benefits and diabetes preventive strategies of ten edible mushrooms. Thirteen of the varieties—mainly because of their polysaccharide and vitamin D content—have anti-diabetic qualities. Of the species that have been investigated the most, Pleurotus, Grimola, and Ganoderma are the only 11 that have demonstrated anti-diabetic capabilities. Further investigation is required to examine the possible medicinal uses of mushrooms, including the connection between vitamin D deficiency and insulin resistance.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

ChatGPT is an AI tool that delivers generic information, but it should not be relied on for expert guidance. It is not a licenced professional and does not provide legal, medical, or financial advice. The AI cannot guarantee the correctness or completeness of the data, and its developers and operators accept no responsibility for any errors or inaccuracies. External links supplied by the AI are for convenience and informational reasons only, and do not constitute endorsements. Users are responsible for verifying facts and making their own choices. The AI is supplied "as is" and without warranty.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Adhikari MK, Watanabe K, ParajuliG. A new variety of *Pholiotamicrospora* (Agaricales) from Nepal. Biodiversitas J. Biol. Divers. 2014;2014(15):101–103.
2. Asrafuzzaman M, Rahman M, Mandal M, Marjuque M, Bhowmik D, Begum R,et al. Oyster mushroom functions as an anti-hyperglycaemic through phosphorylation of AMPK and increased expression of GLUT4 in type 2 diabetic model rats. J. Taibah Univ. Med. Sci. 2018;2018(13):465–471.
3. Ali Sangi S,Bawadekji A, Al Ali M. Comparative effects of metformin, Pleurotus ostreatus, Nigella sativa, Zingiber officinale on the streptozotocin-induced diabetes mellitus in rats. Pharmacogn. Mag. 2018;2018(14):268–273.
4. Bao D, Gong M, Zheng H, Chen M, Zhang L, Wang H, Jiang J, Wu L, Zhu Y, Zhu Gs,et al. Sequencing and comparative analysis of the straw mushroom (*Volvariella volvacea*) genome. PLoS ONE.2013;2013(8):e58294.
5. Blumfield M, Abbott K, Duve E,Cassettari T, Marshall S,Fayet-Moore F Examining the health effects and bioactive components in *Agaricus bisporus* mushrooms: A scoping review. J. Nutr. Biochem. 2020;2020(84):108453.
6. Chakraborty B, Chakraborty U, Barman S, Roy S. Effect of different substrates and casing materials on growth and yield of *Calocybe indica* (P&C) in North Bengal, India. J. Appl. Nat. Sci. 2016s;2016(8):683–690.
7. Cid-Ruzafa J,et al. Vascular complications in patients with type 2 diabetes: Prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc. Diabetol. 2018;2018(17):150.
8. Diyabalanage T,Mulabagal V, Mills, G. Dewitt D, Nair M. Health-beneficial qualities of the edible mushroom, *Agrocybeaegerita*. Food Chem. 2008;2008(108):97–102.
9. Duvnjak L, Duvnjak M. The metabolic syndrome—an ongoing story. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2009;60(Suppl. 7):19–24.

10. He X, Wang X, Fang J, Chang Y, Ning N, Guo H, Huang L, Huang X, Zhao Z. Polysaccharides in *Grifolafrondosa* mushroom and their health promoting properties: A review. Int. J. Biol. Macromol. 2017;101:910–921.
11. Kulkarni, Supriya, Santosh Joshi, HrudayanathThatoi. Temitomycesheimii–A nutritious and medicinally important wild edible mushroom of Similipal forests, Odisha boosting tribal health and Economy. Asian Journal of Biology.2022;16(2):21-32.
Available:https://doi.org/10.9734/ajob/2022/v16i2298
12. Canpolat ŞEY, Canpolat. antioxidant and antimicrobial activity of a medicinal mushroom, ganoderma lucidum. Journal of Advances in Biology & Biotechnology.2023;26(11):60-67.
Available:https://doi.org/10.9734/jabb/2023/v26i11667
13. Stojkovic D, Smiljkovic M, Ciric A, Glamoclija J, Van Griensven L, Ferreira IC, Sokovic M. An insight into antidiabetic properties of six medicinal and edible mushrooms: Inhibition of α-amylase and α-glucosidase linked to type-2 diabetes. South African Journal of Botany. 2019 Jan 1;120:100-3.
Available:https://www.sciencedirect.com/science/article/pii/S0254629917314205
14. Martel J, Ojcius DM, Chang CJ, Lin CS, Lu CC, Ko YF, Tseng SF, Lai HC, Young JD. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nature Reviews Endocrinology. 2017 Mar;13(3):149-60.
Available:https://www.nature.com/articles/nrendo.2016.142
15. Hoa HT, Wang CL, Wang CH. The effects of different substrates on the growth, yield, nutritional composition of two oyster mushrooms (*Pleurotus ostreatus* and *Pleurotus cystidiosus*). Mycobiology. 2015;43:423–434.
16. Hu Y-N, Sung T-J, Chou C-H, Liu K-L, Hsieh L-P, Hsieh C-W. Characterization and antioxidant activities of yellow Strain *Flammulinavelutipes* (Jinhua Mushroom) polysaccharides and their effects on ROS content in L929 cell. Antioxidants,2019;2019(8):298.
17. Karun N, Sharma B, Sridhar K. Biodiversity of macrofungi in Yenepoya Campus, Southwest India. Microb. Biosyst. 2018;2018(3):1–11.
18. Kleftaki SA,Simati S,Amerikanou C,Gioxari A,Tzavara C,Zervakis GI,et al. Pleurotus eryngii improves postprandial glycaemia, hunger and fullness perception, enhances ghrelin suppression in people with metabolically unhealthy obesity. Pharmacol. Res. 2022;2022:175, 105979.
19. Kosiborod M, Gomes MB, Nicolucci A, Pocock S, RathmannW, Shestakova MV,et al. Enhancing the nutritional and functional properties of Pleurotus citrinopileatus mushrooms through the exploitation of winery and olive mill wastes. Food Chem. 2022;2022(370):131022.
20. Liang C, Tian D, Liu Y, Li H, Zhu J, Li M, Xin M, Xia J. Review of the molecular mechanisms of *Ganoderma lucidum* triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y. Eur. J. Med. Chem. 2019;2019(174):130–141.
21. Lin CP, Tsai S-Y. Differences in the moisture capacity and thermal stability of Tremella fuciformis polysaccharides obtained by various drying processes. Molecules.2019;2019(24):2856.
22. Ma G, Yang W, Zhao L, Pei F, Fang D, Hu Q. A critical review on the health promoting effects of mushrooms nutraceuticals. Food Sci. Hum. Wellness.2018;2018(7):125–133.
23. Masaphy S, Zabari L, Goldberg D, Jander-Sha0gug G. The complexity of Morchella systematics: A case of the yellow morel from Israel. Fungi.2010;2010(3):14–18.
24. Misra A, Ramchandran A, Jayawardena R, Shrivastava U, Snehalatha C. Diabetes in South Asians. Diabet. Med. 2014;2014(31):1153–1162.
25. Montoya L, Herrera M, Bandala VM, Ramos A. Two new species and a new record of yellow Cantharellus from tropical Quercus forests in eastern Mexico with the proposal of a new name for the replacement of *Craterellusconfluens*. MycoKeys.2021;2021(80):91.
26. Ndisang JF, Rastogi S,Vannacci A. Insulin resistance, type 1 and type 2 diabetes, related complications 2015. J. Diabetes Res. 2015;2015:234135.
27. Ndisang JF,Vannacci A, Rastogi S. Insulin resistance, type 1 and type 2 diabetes, related complications 2017. J. Diabetes Res. 2017;2017:1478294.
28. Patel DK, Dutta SD, Ganguly K, Cho SJ, Lim KT. Mushroom-derived bioactive molecules as immunotherapeutic agents: A review. Molecules. 2021;26:1359.

29. Rahman M, Akter R. Diabetes ameliorating effect of mushrooms. J. Nov. Physiother. 2021;2:9–13.
30. Senthilarasu G. The lentinoid fungi (Lentinus and Panus) from Western Ghats, India. IMA Fungus. 2015;6: 119–128.
31. Slusarczyk J, Adamska E,Czerwik-Marcinkowska J. Fungi and algae as sources of medicinal and other biologically active compounds: A review. Nutrients. 2021;13:3178.
32. Song Q, Teng AG, Zhu Z. Chemical structure and inhibition on _-glucosidase of a novel polysaccharide from *Hypsizygusmarmoreus*. J. Mol. Struct. 2020;1211:128110.
33. Thu ZM, Myo KK, Aung HT,Clericuzio M, Armijos C,Vidari G. Bioactive phytochemical constituents of wild edible mushrooms from southeast Asia. Molecules. 2020;25:1972.
34. Tiane C,Finimundy T, José A, Dillon P, Antônio J, Henriques JA, Ely M.. A review on general nutritional compounds and pharmacological properties of the Lentinula edodes mushroom. Food Nutr. Sci. 2014;5:1095–1105.
35. Ukwuru M, Muritala A, Eze L. Edible and non-edible wild mushrooms: Nutrition, toxicity and strategies for recognition. J. Clin. Nutr. Metab. 2018;2:9.
36. Vitak T,Yurkiv B, Wasser S, Nevo E,Sybirna N. Effect of medicinal mushrooms on blood cells under conditions of diabetes mellitus. World J. Diabetes. 2017;8:187–201.
37. Wu D, Yang S, Tang C, Liu Y, Li Q, Zhang H,et al. Structural properties and macrophage activation of cell wall polysaccharides from the fruiting bodies of *Hericium erinaceus*. Polymers. 2018;10:850.
38. Wu H, Chen J, Li J, Liu Y, Park H, Yang L. Recent advances on bioactive ingredients of *Morchella esculenta*. Appl. Biochem. Biotechnol. 2021;193:4197–4213.
39. Xiao C, Jiao C, Xie Y, Ye L, Li Q, Wu Q. *Grifolafrondosa* GF5000 improves insulin resistance by modulation the composition of gut microbiota in diabetic rats. J. Funct. Foods. 2021;77:104313.
40. Xiao Y, Chen L, Fan Y, Yan P, Li S, Zhou X. The effect of boletus polysaccharides on diabetic hepatopathy in rats. Chem-Biol. Interact. 2019;308:61–69.

Peer-review history:
The peer review history for this paper can be accessed here:
https://prh.mbimph.com/review-history/3788